Current Research Studies
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pioneer 1 (LAHV)
What is the goal of the study?
This study is being done to see how safe lasmiditan is and how well it will work to help people with migraines. This study will see how lasmiditan compares to placebo for treating migraine attacks in young people.
Who can participate in the study?
This study may be a good fit for children who: Are at least 6 years old and less than 18 years old at Visit 1 Weigh at least 15 kilograms Have been diagnosed with migraines Can swallow tablets You and your family agree not to post information about the study on any website or on social media